Payvision wins the Best PSP award at Merchant Payments Ecosystem 2017
AMSTERDAM, Netherlands, 2017-02-23 09:00 CET (GLOBE NEWSWIRE) -- Payvision, global acquirer and data-driven omnichannel solutions provider, won the award for the Best PSP at the annual Merchant Payments Ecosystem conference, recognizing its innovative global services under the Acapture brand. Integrating Acapture’s omnichannel solution into its global acquiring network, Payvision has transformed itself into a data-driven omnichannel enterprise. This has positioned the company as THE no. 1 merchant acquirer and payment provider empowered by data science and analytics.
“It is an absolute honor for us to be acknowledged as the Best PSP by an industry authority such as MPE. This highlights the focus and dedication we have for our customers and partners”, said Gijs op de Weegh, Chief Operating Officer at Payvision and Acapture. “Merchants need a global solution that offers them a wide variety of payment products for their ecommerce business. We built Acapture with one specific goal in mind: to set a new standard in the payments industry. By using the latest technologies, we offer merchants a complete omnichannel solution to maximize their revenue. This award is a great indicator that our work is appreciated and recognized within the industry.”
Payvision and Acapture’s award-wining product features include a simplified allocation of funds to multiple parties from a single transaction, data science management for improved authorization rates, a one-day integration using one RESTful API, flexible, consolidated reporting, a streamlined reconciliation process, global card acquiring and the ability to handle desktop, mobile and point-of-sale transactions, 80+ of the most popular alternative payment methods, and 160+ transaction currencies.
With a full suite of omnichannel payment features and data analytics in place on one single secure platform, Payvision enables merchants to keep their payment processes running seamlessly. This gives shoppers the freedom and security to choose their most familiar payment method, and leads to increased global conversion rates.
The top European conference, Merchant Payments Ecosystem, hosted in Berlin this month, gathered all the key experts to discuss the most up-to-date industry insights, ending with the prestigious 2017 Awards. The Best PSP award was evaluated by a panel of independent payments industry experts.
About Payvision and Acapture
Awarded with Best Acquirer at MPE Berlin 2016 and Best Merchant Acquirer/Processor at the 2015 Payments Awards, Payvision is one of the fastest-growing global acquiring networks in the world. In the last decade, Payvision has independently built an international acquiring network connecting banks, PSPs, ISOs and their global merchants in the USA, Europe, Asia and the Pacific. Payvision simplifies the complexity of cross-border ecommerce through a single, highly secure payment processing platform for all transactions processed worldwide, with domestic processing, a next-generation reporting interface, and a solid risk management solution.
Together with its subsidiary company, Acapture – a new, scalable, global omnichannel PSP – Payvision combines the experience of an industry leader and the flexibility and speed of a start-up, transforming itself into a data-driven omnichannel enterprise. Payvision and Acapture maximize the revenues of merchants and help them grow their business globally through a data-driven omnichannel approach, and a reliable payment platform. Acapture’s system features SlicePay for simplified allocation of funds to multiple parties from a single transaction, data science management for improved authorization rates, a one-day integration using one RESTful API, flexible, consolidated reporting, a streamlined reconciliation process, and the ability to handle 80+ of the most popular alternative payment methods and 160+ transaction currencies.
Payvision is headquartered in Amsterdam and, over the past decade, the company has expanded its geographical footprint in over 40 countries with offices in New York, Utah, San Francisco, Madrid, London, Toronto, Singapore, Tokyo, Hong Kong, Macau, and Auckland.
For more information about Payvision, please check www.payvision.com and follow us on Twitter @payvision, LinkedIn, Facebook, YouTube, and Corporate blog.
For more information about Acapture, please check www.acapture.com and follow us on Twitter @Acapture_Global, LinkedIn, Facebook, YouTube and Corporate blog.
For further information, please contact:
Alina Geosanu | PR & Communications Assistant; e-mail: firstname.lastname@example.org;
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
Kofax Wins "Most Innovative Solution for Banking Customer Authentication" Award for Third Consecutive Year18.10.2017 08:00 | Pressemelding
Grand Prix Banque & Innovation Honor Recognizes Kofax Mobile ID Customer Onboarding Solution and its Anti-Fraud Capabilities IRVINE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Kofax ®, a leading provider of software to simplify and transform the First Mile(TM) of business, today announced that Kofax Mobile ID(TM) has won "Most Innovative Solution for Banking Customer Authentication" in the 2017 Grand Prix Banque & Innovation Awards in Paris, France. Now in its fourth year, the Awards identify excellence and innovation in the banking sector. The program acknowledges technology companies that have launched and implemented the most outstanding banking-related software solutions, initiatives and projects in France over the past twelve months. This award highlights the new facial recognition and ID verificationfeatures of Kofax Mobile ID that determine the authenticity and validity of identification documents and their holders.
World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer18.10.2017 06:25 | Pressemelding
YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference from the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new advancements surrounding the discovery of PD-1 and PD-L1, including a discussion from the researcher credited with discovering PD-1, as well as interventions to prevent lung cancer and improve quality of life for lung cancer patients. Innovations in lung cancer treatment linked to the discovery of PD-1 Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared an update on how PD-1 blockers have been widely used to treat many types of cancers. After decades of study, research into PD-1 has led to breakthrough immunotherapy treatments that are being hailed as a "penicillin moment" in cancer treatment. "I believe that, just as a number of antibiotics developed in the wake of the discovery of penicillin now p
Barings Supports New Mountain Capital Investment in DRB Systems17.10.2017 16:30 | Pressemelding
CHARLOTTE, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as a Joint Lead Arranger on a Senior Secured Credit Facility to support New Mountain Capital's acquisition of DRB Systems LLC. Founded in 1984 and based in Akron, Ohio, DRB Systems is the leading provider of turnkey technology solutions used to enhance the operational efficiency of car wash sites across the U.S. DRB's integrated technology offering includes hardware and software used in point-of-sale and tunnel control systems as well as ancillary modules to support marketing, human resources, and business analytics. "New Mountain Capital is pleased to have completed its investment in DRB Systems," said Jack Qian, Director of New Mountain Capital. Laura Holson, Head of Capital Markets at New Mountain added, "We deeply value Barings' support as a financing pa
Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds17.10.2017 16:12 | Pressemelding
SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year's American Association for Cancer Research's International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th. CrownBio's scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation. On
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 201717.10.2017 15:15 | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results prior to market open on Tuesday, October 31, 2017. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations se
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions17.10.2017 08:16 | Pressemelding
YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured groundbreaking findings in the study of both small cell and non-small cell lung cancer. The studies presented covered broad research areas, from confirmation of existing classification criteria to ensuring viability of evidence to supporting the use of specific interventions. Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. These results may lead to further evaluation of the scoring system for predicting DLL3-targeted therapeutic efficacy and clinical significance of DLL3 expression in high-grade pulmonary neuroendocrine carcinomas.
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom